 CRANBURY, N.J., Nov. 23, 2020 GLOBE NEWSWIRE -- PMV Pharmaceuticals, Inc. Nasdaq: PMVP, a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced dosing of the first patient in its Phase 12 clinical trial evaluating PC14586, the companys investigational lead compound that targets the Y220C mutant of p53. The trial will enroll up to 130 patients with advanced solid tumors that have the specific p53 Y220C variant. 